Search company, investor...

LXN Corporation


Acquired | Acquired

Total Raised




About LXN Corporation

LXN Corporation offers a personal blood glucose control system

Headquarters Location

6325 Lusk Boulevard

San Diego, California, 92121,

United States


Missing: LXN Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LXN Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing LXN Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LXN Corporation is included in 1 Expert Collection, including Diabetes.



1,903 items

LXN Corporation Frequently Asked Questions (FAQ)

  • Where is LXN Corporation's headquarters?

    LXN Corporation's headquarters is located at 6325 Lusk Boulevard, San Diego.

  • What is LXN Corporation's latest funding round?

    LXN Corporation's latest funding round is Acquired.

  • How much did LXN Corporation raise?

    LXN Corporation raised a total of $57.91M.

  • Who are the investors of LXN Corporation?

    Investors of LXN Corporation include Diabetes Diagnostics, MedVenture Associates, Child Health Corporation of America, Advent International, Premier Medical Partner Fund and 13 more.

  • Who are LXN Corporation's competitors?

    Competitors of LXN Corporation include Sotera Wireless, OptiScan Biomedical, Vytrace, Novoculi, ArKal Medical and 9 more.

Compare LXN Corporation to Competitors

Advanced BioSensors

Advanced BioSensors is developing a miniaturized blood glucose sensor for use in the treatment of diabetes.

ArKal Medical

Arkal Medical is developing a continuous blood glucose sensor for diabetes.

Luminous Medical

Luminous Medical is developing a new device to allow the near continuous measurement of blood glucose and other analytes in the hospital environment.

Bay Area Digital Logo
Bay Area Digital

Bay Area Digital is a company that received a SBIR Phase I grant for a project entitled: Talking Blood Glucose Meter with full Accessibility for Blind, Visually and Cognitively Impaired. Their Project addresses a crisis in the lack of effective glucose monitoring equipment for visually and cognitively impaired diabetics. The proposal thoroughly examines the technical and commercial feasibility of developing innovative technology that enables such patients to reliably use information provided by a state-of-the-art blood glucose meter, using speech output that is coupled with a commercially developed meter. There are currently no state-of-the-art or best-of-breed blood glucose meter systems available in the U.S. market with speech capabilities for use by the cognitively, visually impaired or blind community. The development of such a meter will positively impact the self-management of diabetes mellitus, improving quality of life and clinical outcomes for patients and preventing the development of secondary complications and provide an opportunity to impact a major health problem affecting millions of U.S. citizens.


Speckodyne Corp aims to be a provider of continuous real-time blood coagulability monitoring technology in Operation Room, Catheterization Lab or Intensive Care Unit settings. Based on a approach developed at UCF's College of Optics & Photonics, Speckodyne's blood coagulability monitor uses optical fiber and solid-state optics technology, leading to a robust, relatively inexpensive design that can be easily integrated with existing interventional devices such as catheters and guidewires, as well as bed-side or laboratory equipment.

Sotera Wireless

Sotera Wireless is committed to the development, marketing and sale of a new generation early detection surveillance monitoring system. Its flagship product, the ViSi Mobile, is designed to improve patient safety by detecting early signs of deterioration in virtually any care setting, enabling early intervention and rapid response without limiting the patient's freedom of movement

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.